TrialA Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
Trial details
- Registry ID
- NCT04668339
- Phase
- Phase 2
ARCT
Arcturus Therapeutics, Inc.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceOpen Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Trial details
- Registry ID
- NCT04728347
- Phase
- Phase 2
Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Trial details
- Registry ID
- NCT05526066
- Phase
- Phase 2
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Trial details
- Registry ID
- NCT06279871
- Phase
- Phase 3
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Trial details
- Registry ID
- NCT06488313
- Phase
- Phase 2
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Trial details
- Registry ID
- NCT06747858
- Phase
- Phase 2
Latest recorded trial changes
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858 · Arcturus Therapeutics, Inc.
Planned enrollment increased by 21 participants
− Before
12 participants (planned)
+ After
33 participants (planned)
Primary completion date changed
− Before
Dec 2025
+ After
Jun 2027
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
NCT06279871 · Arcturus Therapeutics, Inc.
Actual enrollment increased by 15 participants
− Before
1499 participants (actual)
+ After
1514 participants (actual)
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
NCT06279871 · Arcturus Therapeutics, Inc.
Actual enrollment decreased by 15 participants
− Before
1514 participants (actual)
+ After
1499 participants (actual)
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
NCT06279871 · Arcturus Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: SARS-CoV-2 neutralizing antibody titers
Measure: SARS-CoV-2 neutralizing antibody seroconversion rates
Measure: Hemagglutination Inhibition (HI) titers
Measure: SARS-CoV-2 neutralizing antibody titers
+ After
Measure: Groups 2a and 2b and ARCT-154-J01 Historical Control: Geometric Mean Titers (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Titers Against Omicron XBB.1.5 Subvariant at Day 29 Measure: Groups 2a and 2b and ARCT-154-J01 Historical Control: Number of Participants With Seroconversion to SARS-CoV-2 Neutralizing Antibody Against Omicron XBB.1.5 Subvariant at Day 29 Measure: Groups 1a and 3a: Adjusted Hemagglutination Inhibition (HI) GMTs Against Influenza Vaccine Strains at Day 29 Measure: Groups 1a and 2a: Adjusted GMTs of SARS-CoV-2 Neutralizing Antibody Against Omicron XBB.1.5 Subvariant at Day 29